双特异性抗体的免疫原性

Immunogenicity of bispecific antibodies

双特异性抗体能够识别并结合两种不同抗原的抗体,与普通抗体药物相比具有灵敏度高、特异性强、以及能够同时阻断多条疾病通路的优势。迄今为止,全球共有3款双特异性抗体药物已上市,近100种双特异性抗体在研,展现出广阔的开发前景。双特异性抗体药物的免疫原性指其进入体内后会引起机体免疫反应产生抗药抗体,可能对药物的药代动力学、药效动力学性质产生影响。本文对卡妥索单抗(catumaxomab)、博纳吐单抗(blinatumomab)、艾美赛珠单抗(emicizumab)的免疫原性相关研究进展进行综述,以期为双特异性抗体的安全性、有效性以及临床合理应用提供参考。

The term bispecific antibody(bsAb)is used to describe antibodies that can recognize and bind two different antigens.Compared with the regular therapeutic antibodies,bsAbs have many advantages,such as higher sensitivity,better specificity,and are able to block multiple disease pathways simultaneously.So far,3 bispecific antibodies have been marketed and nearly 100 are in clinical development all over the world,showing a broad development prospect.Immunogenicity of bispecific antibodies refers to the fact that the drugs will cause the immune response and produce anti-drug antibodies after entering the body,which may affect the pharmacokinetic and pharmacodynamic properties of the drugs.In this paper,the research progress on the immunogenicity of catumaxomab,blinatumomab and emicizumab was reviewed,with a view to providing reference for the safety,efficacy,and rational clinical application of bispecific antibodies.